CCXI - ChemoCentryx solid tumors candidate shows immune stimulation properties in phase 1 trial

Pharmacodynamic results from a phase 1 trial demonstrated that ChemoCentryx's (CCXI) CCX559 exhibits immune stimulatory properties in cancer patients. CCX559 is an inhibitor of PD-L1 that is given in pill format. Currently available PD-L1 inhibitors are monoclonal antibodies that must be given via infusion. The company added that CCX559 could have advantages over antibodies with improved penetration into solid tumors, reduced immunogenicity, and fewer side effects. Pharmacokinetics data also indicated the candidate had good oral availability and expected half-life. Seeking Alpha contributor Avisol Capital Partners gives ChemoCentryx (CCXI) a hold rating.

For further details see:

ChemoCentryx solid tumors candidate shows immune stimulation properties in phase 1 trial